1-(3-Fluorophenyl)sulfonylazetidine-3-carboxylic acid | 1378719-30-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3-Fluorophenyl)sulfonylazetidine-3-carboxylic acid
• CAS: 1378719-30-2
• 化学式: C₁₀H₁₀FNO₄S
• 分子量: 259.258
• InChiKey: DSORINOHDREPQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(3-Fluorophenyl)sulfonylazetidine-3-carboxylic acid 、 1-(4-吡啶基)哌嗪 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 [1-(3-Fluorophenyl)sulfonylazetidin-3-yl]-(4-pyridin-4-ylpiperazin-1-yl)methanone
  参考文献：
  名称：

  Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012

  摘要：

  This Paper describes the continued optimization of an MLPCN probe molecule M-1 antagonist (ML012) through an iterative parallel synthesis approach. After several rounds of modifications of the parent compound, we arrived at a new azetidine scaffold that displayed improved potency while maintaining a desirable level of selectivity over other muscarinic receptor subtypes. Data for representative molecules 7w (VU0452865) and 12a (VU0455691) are presented. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.018
• 作为产物：
  描述：

  3-氟苯磺酰氯 在 水 、 三乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 1-(3-Fluorophenyl)sulfonylazetidine-3-carboxylic acid
  参考文献：
  名称：

  Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012

  摘要：

  This Paper describes the continued optimization of an MLPCN probe molecule M-1 antagonist (ML012) through an iterative parallel synthesis approach. After several rounds of modifications of the parent compound, we arrived at a new azetidine scaffold that displayed improved potency while maintaining a desirable level of selectivity over other muscarinic receptor subtypes. Data for representative molecules 7w (VU0452865) and 12a (VU0455691) are presented. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.018

文献信息

• [EN] AZETIDINE DERIVATIVES FOR THE TREATMENT OF INTEGRIN ASSOCIATED DISEASES<br/>[FR] DÉRIVÉS D'AZÉTIDINE POUR LE TRAITEMENT DE MALADIES SE RAPPORTANT AUX INTÉGRINES
  申请人：UNIV NOTTINGHAM

  公开号：WO2022008918A1

  公开（公告）日：2022-01-13

  The invention relates to novel compounds of formula (I), the compounds being capable of acting as avβ6 integrin antagonists, their use in the treatment of disease, their methods of manufacture and compositions comprising said compounds for such purposes (I) wherein R1 is selected from: R1a, -C(O)R1a, -C(O)OR1a -C(O)NHR1a, -C(O)N(R1a)2, -SO2R1a, wherein R1a are each independently selected from: alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, each of which may be optionally substituted; R2 is selected from: hydrogen, halogen, optionally substituted alkyl or optionally substituted alkoxyl; R2a are each independently selected from: hydrogen, halogen, optionally substituted alkyl or optionally substituted alkoxyl; R3 is selected from: hydrogen, optionally substituted alkyl or optionally substituted alkoxyl; R4 is hydroxyl; Ar1 is an optionally substituted heteroaryl or bicyclic heteroaryl; and L is a linker; or a pharmaceutically acceptable salt thereof.

  该发明涉及公式（I）的新化合物，这些化合物能够作为avβ6整合素拮抗剂发挥作用，它们在治疗疾病中的用途，它们的制备方法以及包含这些化合物的用于此类目的组合物（I），其中R1从以下中选择：R1a，-C（O）R1a，-C（O）OR1a，-C（O）NHR1a，-C（O）N（R1a）2，-SO2R1a，其中R1a各自独立选择自：烷基，烯烃基，炔烃基，芳基，杂芳基，烷基芳基或烷基杂芳基，每种均可选择性取代；R2从以下中选择：氢，卤素，可选择性取代的烷基或可选择性取代的烷氧基；R2a各自独立选择自：氢，卤素，可选择性取代的烷基或可选择性取代的烷氧基；R3从以下中选择：氢，可选择性取代的烷基或可选择性取代的烷氧基；R4为羟基；Ar1为可选择性取代的杂芳基或双环杂芳基；L为连接物；或其药用可接受盐。
• Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012
  作者：Bruce J. Melancon、Thomas J. Utley、Christian Sevel、Margrith E. Mattmann、Yiu-Yin Cheung、Thomas M. Bridges、Ryan D. Morrison、Douglas J. Sheffler、Colleen M. Niswender、J. Scott Daniels、P. Jeffrey Conn、Craig W. Lindsley、Michael R. Wood

  DOI：10.1016/j.bmcl.2012.06.018

  日期：2012.8

  This Paper describes the continued optimization of an MLPCN probe molecule M-1 antagonist (ML012) through an iterative parallel synthesis approach. After several rounds of modifications of the parent compound, we arrived at a new azetidine scaffold that displayed improved potency while maintaining a desirable level of selectivity over other muscarinic receptor subtypes. Data for representative molecules 7w (VU0452865) and 12a (VU0455691) are presented. (c) 2012 Elsevier Ltd. All rights reserved.